REFERENSI
SCHELLHAMMER, Paul F. An evaluation of bicalutamide in the treatment of prostate cancer. Expert Opinion on Pharmacotherapy, 2002, 3.9: 1313-1328.
BOHL, Casey E., et al. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proceedings of the National Academy of Sciences, 2005, 102.17: 6201-6206.
OSGUTHORPE, D. J.; HAGLER, A. T. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Biochemistry, 2011, 50.19: 4105-4113.
GU, Weijie, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. The Lancet Oncology, 2022, 23.10: 1249-1260.
